Full-Time
Posted on 6/27/2025
Develops single-dose genomic medicines via epigenetics
No salary listed
Boston, MA, USA
In Person
Chroma Medicine focuses on genomic medicine by developing single-dose epigenetic therapies. Its treatments aim to regulate gene expression through changes in chromatin structure rather than altering the DNA sequence, allowing lasting effects as cells divide. The approach uses the body’s natural gene-control system to create therapeutics that can durably modify gene activity with a one-time treatment. The company differentiates itself by targeting epigenetic chromatin remodeling to modulate genes without DNA edits, pursuing a research-and-development business model to build a new class of genomic medicines. Its goal is to expand genomic medicine by offering therapies that safely control gene expression to treat a range of diseases, supported by ongoing research, funding, and team expansion.
Company Size
11-50
Company Stage
Series B
Total Funding
$260M
Headquarters
Boston, Massachusetts
Founded
2021
Help us improve and share your feedback! Did you find this helpful?
Hybrid Work Options
Chroma Medicine secures $135M in Series B financing to advance breakthrough epigenetic editing technology and expand pipeline of durable precision genomic medicines. News provided by. Funding to progress Chroma's single-dose epigenetic editing therapies and support expansion of novel genetic medicine platform designed to enable precise gene regulation while preserving genomic integrity Financing led by GV, with participation from ARCH Venture Partners, DCVC Bio, Mubadala Capital, Sixth Street, and all existing investors CAMBRIDGE, Mass., March 1, 2023 /PRNewswire/ - Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced the completion of a $135 million Series B financing led by GV (Google Ventures), with participation from additional new investors ARCH Venture Partners, DCVC Bio, Mubadala Capital, Sixth Street, and all existing investors, including Alexandria Venture Investments, Atlas Venture, Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Newpath Partners, Omega Funds, Osage University Partners, Sofinnova Partners, T Rowe Price, and Wellington Management. The financing will support advancement of Chroma's therapeutic programs toward the clinic, and continued investment in the company's core epigenetic editing platform. "In the year since launch, we have made significant progress in advancing the pioneering work of our scientific founders towards harnessing the power of the cell's epigenome to regulate gene expression and developing a robust portfolio of single-dose epigenetic editing therapeutics," said Catherine Stehman-Breen, M.D., CEO of Chroma. "We're grateful to this exceptional syndicate of investors, whose commitment enables our ongoing drive to introduce this new class of precision genomic medicines with curative potential to patients with serious illnesses." Current gene editing approaches regulate gene expression by cutting or nicking DNA, introducing risks associated with leveraging unpredictable DNA repair pathways. Chroma's single-dose epigenetic editors harness the cells' innate mechanism for gene regulation to precisely and durably silence, activate, and multiplex genes using a single platform, without changing the underlying DNA sequence. This groundbreaking approach enables Chroma to more effectively address a wide range of diseases and to target multiple pathways for complex diseases. "Epigenetic editing opens the possibility of pursuing targets on the genome previously intractable with other therapeutic modalities; this includes the ability to target both protein coding and non-coding RNAs," said Vic Myer, Ph.D., CSO of Chroma. "Our approach enables precise regulation while avoiding break-induced mutations, translocations, and rearrangements associated with other technologies, removing limitations on the number of simultaneous edits that are possible." "Genomic medicine is an exciting and fast-evolving field, and epigenetic editing has emerged as a promising new frontier for gene regulation," said Issi Rozen, Venture Partner, GV. "Chroma's technology enables durable modulation of gene expression - both individual genes and multiple genes at once - providing potentially transformative treatments for patients living with serious diseases." About Chroma Medicine Chroma Medicine is a biotechnology company pioneering a new class of genomic medicines that harness epigenetics, nature's innate mechanism for gene regulation, to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. For more information, please visit chromamedicine.com or follow the company on LinkedIn and Twitter. SOURCE Chroma Medicine
Chroma Medicine and Nvelop Therapeutics unite to form nChroma Bio to redefine the future of in vivo targeted genetic medicine.
Kaplan comes from epigenetic medicine company Chroma Medicine, where he served as president, chief financial and corporate development officer.
Epigenetics is the study of changes in organisms caused by modification of gene expression. By targeting epigenetic mechanisms, epigenetic therapies alter gene expression patterns to treat diseases. Some of these mechanisms include DNA methylation and histone modifications. DNA methylation is the attachment of chemical compounds called methyl groups to DNA so as to activate or silence a gene, whereas histone modifications aim to reduce gene expression by altering chromatin structure, which is the mixture of DNA and proteins that form the chromosomes.In this article, we take a look at six epigenetics biotech companies that are significant as well as up-and-coming players in the industry.Chroma MedicineMassachusetts-based Chroma Medicine has come up with programmable epigenetic editors that target genes and control chromatin conformation. These editors have a DNA binding domain to silence or activate a specific gene and a modular epigenetic effector domain that creates durable methylation patterns to control chromatin conformation and check whether a gene is accessible for transcription. Chromatin conformation is the process that regulates the coordination between DNA replication and transcription.Chroma’s epigenetic editors are able to fully eliminate the expression of the targeted gene as opposed to other current methods that regulate gene expression by cutting the DNA, which in turn may cause unpredictable DNA repair pathways to become activated. Recently, the biotech partnered with the Whitehead Institute for Novel Epigenetic Editing Technology to access a novel technology called CHARM, which is short for coupled histone tail for autoinhibition release of methyltransferase. CHARM uses an epigenetic editing effector domain to recruit and activate endogenous DNA methyltransferases to silence target genes.Earlier this year, it sponsored a preclinical study that found that epigenetic gene silencing can suppress a target gene – in this case, the Pcsk9 gene linked to high cholesterol – further strengthening the science behind epigenetic therapeutics. Last year, the epigenetics company was among The Endpoints 11, and named a top startup to hit the biotech scene with its novel science and technology.Storm TherapeuticsRNA is a key player in cellular decision-making, especially non-coding RNA
License provides exclusive access to innovative epigenetic editors and expands the reach of Chroma's platformBOSTON, June 27, 2024 /PRNewswire/ -- Chroma Medicine, Inc. (Chroma) a genomic medicine company pioneering single-course epigenetic editing therapeutics, today announced it has entered into an exclusive license agreement with the Whitehead Institute to access intellectual property and technology developed in the lab of Chroma co-founder Jonathan Weissman, Ph.D.The novel technology called CHARM (coupled histone tail for autoinhibition release of methyltransferase) uses a compact epigenetic editing effector domain to recruit and activate endogenous DNA methyltransferases to durably silence target genes. CHARM can utilize a self-silencing mechanism to limit its duration of expression and has been shown by Dr. Weissman's lab to induce brain-wide prion protein silencing in vivo.With an aim to deliver on the transformative potential of epigenetic editing, Chroma is expanding the versatility of its platform by leveraging this new technology to rapidly advance a new class of therapeutics that harness epigenetics, nature's innate mechanism for gene regulation, to achieve unparalleled control of gene expression without cutting, nicking, or altering the DNA sequence."This agreement is a powerful example of our deep commitment to innovation in genomic medicines," said Catherine Stehman-Breen, M.D., Chroma's Chief Executive Officer. "Adding CHARM to our arsenal of technologies strengthens our mission to bring a broad portfolio of durable epigenetic editing therapeutics to patients."About Whitehead Institute and Weissman LaboratoryWhitehead Institute is a world-renowned non-profit research institute dedicated to improving human health through basic biomedical research. Whitehead Institute's mission is to forge new frontiers in science, uncovering insights today that unlock the potential of tomorrow.The Weissman Laboratory is looking at how cells ensure that proteins fold into their correct shape, as well as the role of protein misfolding in disease and normal physiology